ATLAS IDE Study Results

Treat anterior and posterior aneurysms with confidence

The ATLAS IDE studies have shown excellent results from the largest pivotal data with high complete occlusion and low complication rates using the Neuroform Atlas® Stent System.

Atlas IDE Study

The Atlas anterior and posterior IDE studies are the largest of its kind, with 298 patients having diverse anatomical locations.

Anterior
Posterior
  Anterior
n=182
Posterior
n=116
Primary efficacy endpoint¹ 84.7% 76.7%
Primary safety endpoint² 4.4% 4.3%
Retreatment³ 3.8% 7.8%

1. Primary efficacy endpoint complete aneurysm occlusion (Raymond-Roy class 1) on 12-month angiography, in the absence of retreatment or parent artery stenosis (>50%) at the target location.
2. Primary safety endpoint of any major ipsilateral stroke or neurological death within 12 months.
3. Retreatment rate.

Atlas Posterior: Jankowitz BT, Jadhav AP, Gross B, et al, Pivotal trial of the Neuroform Atlas stent for treatment of posterior circulation aneurysms: one-year outcomes, Journal of NeuroInterventional Surgery 2022;14:143-148.
Atlas Anterior: Zaidat OO, Hanel RA, Sauvageau EA, et al. Pivotal Trial of the Neuroform Atlas Stent for Treatment of Anterior Circulation Aneurysm. Stroke. 2020; 51:2087 -2094.

"With the additional challenges that come with treating posterior circulation aneurysms, we never would have anticipated reaching occlusion rates that rival those found in the anterior circulation. Now with Neuroform Atlas, those same high rates are achievable."

Dr. Brian Jankowitz